Current Report Filing (8-k)
January 11 2018 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
Current
Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 5, 2018
REGENXBIO INC.
(Exact
Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-37553
|
|
47-1851754
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
9600 Blackwell Road, Suite 210
Rockville, Maryland
|
|
20850
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(240)
552-8181
(Registrants telephone number, including area code)
N/A
(Former name or
former address, if changed since last report)
Check the appropriate box below
if the
Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this
chapter).
Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Effective as of January 5, 2018, Faraz Ali resigned as Chief Business Officer of REGENXBIO Inc. (the Company). The Company has
not entered into a separation agreement with Mr. Ali, but may do so at a later date, in which case the details of the separation agreement will be reported at that time.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
REGENXBIO INC.
|
|
|
|
|
Date: January 11, 2018
|
|
|
|
By:
|
|
/s/ Patrick J. Christmas II
|
|
|
|
|
|
|
Patrick J. Christmas II
|
|
|
|
|
|
|
Senior Vice President, General Counsel
|
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024